About PamGene
PamGene is a company based in United States founded in 1999. It operates as a Professional Services and HealthTech. PamGene has raised $17.89 million across 6 funding rounds from investors including Edmond de Rothschild, Gimv and European Union. PamGene offers products and services including Kinome Profiling Technology, Immuno Oncology Solutions, and Therapeutic Candidate Analysis. PamGene operates in a competitive market with competitors including Inflammatix, Agendia, GenomeDx Biosciences, Affymetrix and Akonni, among others.
- Headquarter Virginia, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pamgene.com
- Social LinkedIn X
- Total Equity Funding$17.89 M (USD)
in 6 rounds
- Latest Funding Round$8.18 M (USD), Grant
Jun 2023
- InvestorsEdmond de Rothschild
& 5 more
Products & Services of PamGene
PamGene offers a comprehensive portfolio of products and services, including Kinome Profiling Technology, Immuno Oncology Solutions, and Therapeutic Candidate Analysis.
Kinome profiling technology is used for cellular signaling analysis.
Solutions for immuno oncology treatment are developed and optimized.
Therapeutic candidates are analyzed and optimized for drug development.
Funding Insights of PamGene
PamGene has successfully raised a total of $17.89M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $8.18 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.9M
- Total Rounds 6
- Last Round Grant — $8.2M
- First Round $6.4M
(Dec 2000)
- Investors Count 6
All 6 funding rounds of PamGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $8.2M | Grant | – | – | |
| Jan 2019 | $456,142 | Grant | – | – | |
| Dec 2017 | $303,774 | Grant | – | – | |
| Jan 2016 | $510,013 | Grant | – | – | |
| Jul 2003 | $11.5M | Series B | – | – | |
| Dec 2000 | $6.4M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in PamGene
PamGene has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Edmond de Rothschild, Gimv and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for PamGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PamGene
3 dated milestones of PamGene across 24 years, from founding to its latest funding, stage changes and deals.
- Founded PamGene is founded.
- Funding First funding round of $6.4M.
- Funding Latest funding round, Grant, of $8.2M.
Competitors of PamGene
PamGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, GenomeDx Biosciences, Affymetrix and Akonni, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.5M | 54 | Provider of diagnostic solutions for systemic infections | |
| agendia.com | 2003 | Irvine, United States | $123.0M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| genomedx.com | 2008 | San Diego, United States | $69.7M | 159 | Genomic tests for urologic cancers are developed and commercialized. | |
| affymetrix.com | 1991 | Santa Clara, United States | – | 721 | Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level | |
| akonni.com | 2003 | Frederick, United States | $39.7M | 12 | Molecular diagnostics for complex infections are developed by Akonni. | |
| kromatid.com | 2007 | Fort Collins, United States | $14.5M | – | Molecular and genetic tests for detecting disease-causing mutations are provided. | |
| indevr.com | 2003 | Boulder, United States | $16.0M | – | Biotherapeutics, vaccines, and diagnostic products are manufactured and developed. | |
| synplogen.com | 2017 | Tsuruoka, Japan | – | – | DNA synthesis technology is developed using microbial methods. | |
| exiqon.com | 1995 | Vedbaek, Denmark | $22.9M | 65 | LNA-based tools are developed for diagnostics and research applications. |
Detailed competitors of PamGene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PamGene
The website of PamGene (pamgene.com) receives about 3K visits a month.
- Monthly visits3K
▼ 8.7% vs previous month
Latest news on Pamgene
Complete news archive for PamGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PamGene
10 companies that operate in the same segment as PamGene (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PamGene
PamGene was founded in 1999 and raised its 1st funding round 1 year after it was founded.
PamGene is headquartered in United States. It is registered at Virginia, United States.
PamGene is a funded company, having raised a total of $17.89M across 6 funding rounds to date. The company's 1st funding round was a Series A of $6.4M, raised on Dec 2000.
PamGene is engaged in supporting physicians and scientists with solutions for patient treatment and disease understanding. The companys multiplex, functional kinase activity profiling technology is utilized to provide insights into cellular signaling. Activities are centered in diagnostics, immuno-oncology treatment optimization, and therapeutic candidate analysis for the pharma and biotech sectors. Mechanistic insights into biological models are also provided through kinome profiling.
PamGene's top competitors include Inflammatix, Agendia and KromaTiD.
PamGene offers Kinome Profiling Technology, Immuno Oncology Solutions, and Therapeutic Candidate Analysis.
PamGene has 6 investors. Key investors include Edmond de Rothschild, Gimv, European Union, Life Sciences Partners, and EIC Fund.